Search | TVST | ARVO Journals

Showing 1 – 20 of 83

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Retina December 2024

Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema

PDF

David S. Boyer; Nathan C. Steinle; Joel A. Pearlman; Cameron M. Stone; Courtney Crawford; Sunil Gupta; Pravin U. Dugel; Megan E. Baldwin; Ian M. Leitch
TAGS: aflibercept, diabetic macular edema, vascular endothelial growth factor a, vascular endothelial growth factor c, vascular endothelial growth factors
Trans. Vis. Sci. Tech.. 2024; 13(12):32. https://doi.org/10.1167/tvst.13.12.32

ARVO Annual Meeting Abstract June 2024

Clinical Characteristics of Choroidal Vitiligo

Christine Morozova; Dan Kamen; David S Boyer; Homayoun Tabandeh

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6657.

ARVO Annual Meeting Abstract June 2024

Protection Against Vision Loss by ANX007: Results from the Phase 2 ARCHER Clinical Trial

David S Boyer

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2791.

ARVO Annual Meeting Abstract June 2024

Photobiomodulation Using the Valeda Multiwavelength Light Delivery System Demonstrates Significant Reduction in Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration

Todd Schneiderman; Victor H Gonzalez; David S Boyer; Richard B Rosen; Samantha Xavier; Allen Hu; David Warrow; Eleonora M Lad; Diana V Do; Allen Ho; Glenn J Jaffe; Marion Ronit Munk; Cindy Croissant; Stephanie Tedford; Rene Ruckert; Clark Tedford

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):379.

ARVO Annual Meeting Abstract June 2024

A multicenter, open-labeled, phase 2a study of AG-73305, a novel bi-specific Fc-fusion protein for the treatment of diabetic macular edema

Tan Nguyen; Sunil Patel; Janet K Cheetham; David S Boyer; Artemis Wu; Larry A Wheeler; Madhu Cherukury

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1759.

ARVO Annual Meeting Abstract June 2024

Oral APX3330, a Ref-1 Inhibitor, Slows Progression of Diabetic Retinopathy on a Binocular DRSS Person-Level Scale

Daniel Su; Jay Stuart Pepose; Barbara Withers; Mitchell G Brigell; Audrey Lazar; Ronil Patel; George Magrath; Peter K Kaiser; David S Boyer

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):958.

ARVO Annual Meeting Abstract June 2023

Exploratory optical coherence tomography (OCT) analysis in patients with geographic atrophy (GA) treated by OpRegen: Results from the Phase 1/2a trial

Eyal Banin; Adiel Barak; David S Boyer; Rita Ehrlich; Allen Ho; Tareq Jaouni; Richard McDonald; Christopher D Riemann; David G Telander; Miao Zhang; Dolly Chang; Avi Ben-Shabat; Gary Hogge; Benjamin Reubinoff

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2826.

ARVO Annual Meeting Abstract June 2023

Clinical Effectiveness of the 0.19-mg Fluocinolone Acetonide (FAc) Intravitreal Implant for Diabetic Macular Edema: Anatomic, Visual and Treatment Burden Outcomes

Christine Morozova; Lucas Humayun; Homayoun Tabandeh; David S Boyer; Pouya N Dayani; Firas M Rahhal

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2652.

ARVO Annual Meeting Abstract June 2023

Open-label Phase 2a study of AG-73305, a novel bi-specific Fc-fusion protein for the treatment of diabetic macular edema

Sunil Patel; Janet K Cheetham; Tan Nguyen; David S Boyer; Artemis Wu; Ben Chang; Larry A Wheeler; Madhu Cherukury

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2642.

ARVO Annual Meeting Abstract June 2023

Efficacy and safety of MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: A phase 2b randomized, sham-controlled, multi-center, multi-dose, double-masked clinical trial (RESTORE)

David S Boyer; Lance Bergstrom; Andres Emanuelli; Victor H Gonzalez; Charles Clifton Wykoff; Sunil Gupta; David S Liao; Vitaliy Zak; Sai H Chavala; Samar Mohanty; subrata bataybal; Jody Piltz-Seymour; Ananta Ayyagari; John Koester; Aaron Osborne

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5443.

ARVO Annual Meeting Abstract June 2023

ZETA-1 Phase 2 Trial to Determine the Safety and Efficacy of APX3330: a Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy

Daniel Su; Jay Stuart Pepose; Mark R Kelley; Audrey Lazar; Louis Haddad; Mina Sooch; Mitchell G Brigell; Peter K Kaiser; David S Boyer

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3753.

ARVO Annual Meeting Abstract June 2023

LIGHTSITE III 24-Month Analysis: Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda Light Delivery System

Marion Ronit Munk; Victor Gonzalez; David S Boyer; Richard B Rosen; Samantha Xavier; Allen Hu; David Warrow; Eleonora M.Lad; Diana V Do; Todd Schneiderman; Allen Ho; Glenn J Jaffe; Stephanie Tedford; Cindy Croissant; Rene Ruckert; Clark Tedford

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5059.

ARVO Annual Meeting Abstract June 2023

Effect of tadalafil on progression of age-related macular degeneration

Tracy Lang; John O'Fee; Khristina Lung; David S Boyer; Andrew A Moshfeghi; Brian C Toy

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1135.

Retina March 2023

Sustained Ocular Delivery of Bevacizumab Using Densomeres in Rabbits: Effects on Molecular Integrity and Bioactivity

PDF

Jan S. Peterson; WeiLiam Chen; Barry M. Libin; David S. Boyer; Peter K. Kaiser; Jeffrey M. Liebmann
TAGS: bevacizumab, oryctolagus cuniculus, personal integrity
Trans. Vis. Sci. Tech.. 2023; 12(3):28. https://doi.org/10.1167/tvst.12.3.28

ARVO Annual Meeting Abstract June 2022

LIGHTSITE III (Interim Analysis): Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda Light Delivery System

Marion Ronit Munk; Victor H. Gonzalez; David S Boyer; Diana V Do; Samantha Xavier; Allen Hu; Richard B Rosen; Eleonora Lad; Todd Schneiderman; Allen C Ho; Glenn Jaffe; David Warrow; Stephanie Tedford; Cindy Croissant; Rene Ruckert; clark tedford

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):379 – F0210.

ARVO Annual Meeting Abstract June 2022

Prediction of Activity in Eyes with Macular Neovascularization Due to Age-related Macular Degeneration Using Deep Learning

Ayesha Nuri Karamat; Giulia Corradetti; Nadav Rakocz; Jeffery N Chiang; Muneeswar Gupta nittala; David S Boyer; David Sarraf; Eran Halperin; Srinivas R Sadda

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):206 – F0053.

ARVO Annual Meeting Abstract June 2022

The safety of APX3330, an oral drug candidate for the treatment of diabetic eye disease, in the ongoing masked 24-week ZETA-1 Phase 2 clinical trial

David S Boyer; Mitch Brigell; Ajay Kolli; Kavon Rahmani; Audrey Lazar; Mina Sooch; Ronil Patel; Eliot Lazar; Jay Stuart Pepose; Mark R Kelley

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):675 – F0129.

ARVO Annual Meeting Abstract June 2022

Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies.

Roger Goldberg; Jeffrey S Heier; Charles Clifton Wykoff; Giovanni Staurenghi; Rishi P Singh; Nathan Steinle; David S Boyer; Jordi Mones; Frank G Holz; Caleb Bliss; Federico Grossi; Ravi Metlapally; Ramiro Ribeiro

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1500.

ARVO Annual Meeting Abstract June 2022

Safety and Efficacy of a Phase 1/2a Clinical Trial of Transplanted Allogeneic Retinal Pigmented Epithelium (RPE, OpRegen) Cells in Advanced Dry Age-Related Macular Degeneration (AMD)

Allen C Ho; Eyal Banin; Adiel Barak; David S Boyer; Rita Ehrlich; Tareq Jaouni; H Richard MacDonald; Christopher D Riemann; David Telander; Jordi Mones; Avi Ben Shabat; Gary S Hogge; Benjamin Reubinoff

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1862.

ARVO Annual Meeting Abstract June 2022

Localization of the Internal Limiting Membrane Flap After Macular Hole Surgery

Christine Morozova; Andy Morozov; Dan Kamen; Jin Zhang; Rossella Favale; Mark Walsh; Francesco Boscia; David S Boyer; Homayoun Tabandeh

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3404 – F0304.

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema

Clinical Characteristics of Choroidal Vitiligo

Protection Against Vision Loss by ANX007: Results from the Phase 2 ARCHER Clinical Trial

Photobiomodulation Using the Valeda Multiwavelength Light Delivery System Demonstrates Significant Reduction in Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration

A multicenter, open-labeled, phase 2a study of AG-73305, a novel bi-specific Fc-fusion protein for the treatment of diabetic macular edema

Oral APX3330, a Ref-1 Inhibitor, Slows Progression of Diabetic Retinopathy on a Binocular DRSS Person-Level Scale

Exploratory optical coherence tomography (OCT) analysis in patients with geographic atrophy (GA) treated by OpRegen: Results from the Phase 1/2a trial

Clinical Effectiveness of the 0.19-mg Fluocinolone Acetonide (FAc) Intravitreal Implant for Diabetic Macular Edema: Anatomic, Visual and Treatment Burden Outcomes

Open-label Phase 2a study of AG-73305, a novel bi-specific Fc-fusion protein for the treatment of diabetic macular edema

Efficacy and safety of MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: A phase 2b randomized, sham-controlled, multi-center, multi-dose, double-masked clinical trial (RESTORE)

ZETA-1 Phase 2 Trial to Determine the Safety and Efficacy of APX3330: a Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy

LIGHTSITE III 24-Month Analysis: Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda Light Delivery System

Effect of tadalafil on progression of age-related macular degeneration

Sustained Ocular Delivery of Bevacizumab Using Densomeres in Rabbits: Effects on Molecular Integrity and Bioactivity

LIGHTSITE III (Interim Analysis): Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda Light Delivery System

Prediction of Activity in Eyes with Macular Neovascularization Due to Age-related Macular Degeneration Using Deep Learning

The safety of APX3330, an oral drug candidate for the treatment of diabetic eye disease, in the ongoing masked 24-week ZETA-1 Phase 2 clinical trial

Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies.

Safety and Efficacy of a Phase 1/2a Clinical Trial of Transplanted Allogeneic Retinal Pigmented Epithelium (RPE, OpRegen) Cells in Advanced Dry Age-Related Macular Degeneration (AMD)

Localization of the Internal Limiting Membrane Flap After Macular Hole Surgery

To View More...

You must be signed into an individual account to use this feature.